NINJ2 and glioma: Similarly, CRISPR/Cas9-mediated knockout of Ninj2, a modulator of multiple RTKs including FGFR, demonstrated suppression of glioma cell survival and invasiveness, reinforcing broader intersection between RTK signaling and FGFR pathway regulation.274